![Stephen Nava](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Stephen Nava
Corporate Officer/Principal bei Regulator Affairs Quality Assurance Consulting Services, Inc.
Aktive Positionen von Stephen Nava
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Regulator Affairs Quality Assurance Consulting Services, Inc. | Corporate Officer/Principal | 01.01.2004 | - |
Karriereverlauf von Stephen Nava
Ehemalige bekannte Positionen von Stephen Nava
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
BiPar Sciences, Inc.
![]() BiPar Sciences, Inc. Pharmaceuticals: MajorHealth Technology BiPar Sciences, Inc. develops and markets drugs for cancer patients. It offers BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor for metastatic triple negative breast cancer, ovarian cancer, and other malignancies; BSI-401, a follow-on PARP inhibitor candidate for pancreatic cancer; and BSI-301, an iodothyronine program with anti-tubulin properties. The company was founded by Barry M. Sherman, Thomas F. White and Allan Basbaum in 2002 and is headquartered in Bridgewater, NJ. | General Counsel | 01.01.2005 | 01.06.2011 |
Acumen Sciences LLC | General Counsel | 01.01.2002 | 01.01.2004 |
VIRACTA THERAPEUTICS, INC. | Compliance Officer | 09.07.2018 | - |
General Counsel | 09.07.2018 | - |
Ausbildung von Stephen Nava
Texas A&M University-Kingsville | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 6 |
Operativ
General Counsel | 3 |
Compliance Officer | 1 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 4 |
---|---|
Sunesis Pharmaceuticals, Inc.
![]() Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
BiPar Sciences, Inc.
![]() BiPar Sciences, Inc. Pharmaceuticals: MajorHealth Technology BiPar Sciences, Inc. develops and markets drugs for cancer patients. It offers BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor for metastatic triple negative breast cancer, ovarian cancer, and other malignancies; BSI-401, a follow-on PARP inhibitor candidate for pancreatic cancer; and BSI-301, an iodothyronine program with anti-tubulin properties. The company was founded by Barry M. Sherman, Thomas F. White and Allan Basbaum in 2002 and is headquartered in Bridgewater, NJ. | Health Technology |
Acumen Sciences LLC | |
Regulator Affairs Quality Assurance Consulting Services, Inc. |
- Börse
- Insiders
- Stephen Nava
- Erfahrung